UGISense AG is a biotech company dedicated to developing new and innovative antisense drugs in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimeresTM. The company, which was first established in 2016, is being financed by private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Venture Capital Grants program).
View Top Employees from UGISense AG| Website | http://www.ugisense.com |
| Revenue | $3 million |
| Employees | View employees |
| Founded | 2016 |
| Address | Otto-Hahn-Straße 15, Dortmund, Nordrhein-Westfalen 44227, DE |
| Phone | +49 231 97427063 |
| Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Drug Discovery, Therapeutics, Health Care |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies |
Looking for a particular UGISense AG employee's phone or email?
UGISense AG Questions
The UGISense AG annual revenue was $3 million in 2024.
UGISense AG is based in Dortmund, Nordrhein-Westfalen.
The NAICS codes for UGISense AG are [541, 5417, 54171, 54, 541714].
The SIC codes for UGISense AG are [873, 87].
